Search PubMed⌕ Search

Biomedical subjects

I Jonassen

Publications and source records attributed to I Jonassen.

24 records · Page 2Linked to original sources
PubMed1995

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo.

Albumin is a multifunctional transport protein that binds a wide variety of endogenous substances and drugs. Insulins with affinity for albumin were engineered by acylation of the epsilon-amino group of LysB29 with saturated fatty acids containing 10-16 carbon atoms. The association constants for binding of the fatty acid acylated insulins to human albumin are in the order of 10(4)-10(5) M-1. The binding apparently involves both non-polar and ionic interactions with the protein. The acylated insulins bind at the long-chain fatty acid binding sites, but the binding affinity is lower than that of the free fatty acids and depends to a relatively small degree on the number of carbon atoms in the fatty acid chain. Differences in affinity of the acylated insulins for albumin are reflected in the relative timing of the blood-glucose-lowering effect after subcutaneous injection into rabbits. The acylated insulins provide a breakthrough in the search for soluble, prolonged-action insulin preparations for basal delivery of the hormone to the diabetic patient. We conclude that the biochemical concept of albumin binding can be applied to protract the effect of insulin, and suggest that derivatization with albumin-binding ligands could be generally applicable to prolong the action profile of peptide drugs.

Acylation↗
PubMed1995

Finding flexible patterns in unaligned protein sequences.

We present a new method for the identification of conserved patterns in a set of unaligned related protein sequences. It is able to discover patterns of a quite general form, allowing for both ambiguous positions and for variable length wildcard regions. It allows the user to define a class of patterns (e.g., the degree of ambiguity allowed and the length and number of gaps), and the method is then guaranteed to find the conserved patterns in this class scoring highest according to a significance measure defined. Identified patterns may be refined using one of two new algorithms. We present a new (nonstatistical) significance measure for flexible patterns. The method is shown to recover known motifs for PROSITE families and is also applied to some recently described families from the literature.

Algorithms↗
PubMed1993

Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae.

Human tissue factor pathway inhibitor (TFPI) and three derivatives with deletions of: 1) the complete COOH-terminal third of the polypeptide including the third Kunitz domain, 2) the third Kunitz domain alone, or 3) the penultimate basic COOH-terminal region alone were expressed in yeast as secreted products. High expression yield was obtained only with the derivative that lacked both the third Kunitz domain and the penultimate COOH tail (TFPI1-161). The purified short form was heterogeneously glycosylated with a high mannose glycan. The specific activities of the different mutant polypeptides toward FXa.tissue factor.FVIIa in a chromogenic assay were similar to that of TFPI expressed in baby hamster kidney cells, suggesting that correct folding takes place in yeast and that neither the third Kunitz domain nor the COOH-terminal region is required for this activity. However, in a clotting assay the anticoagulant activities of yeast-produced TFPI and the shortened derivative TFPI1-161 were about 5- and 50-fold lower, respectively, than for full-length TFPI from mammalian cells. Clotting assays with purified short form TFPI showed that it acted mainly via inhibition of FVIIa.tissue factor rather than FXa. The anticoagulant activity of short form TFPI was comparable with that of high affinity antibodies toward tissue factor.

Amino Acid Sequence↗
PubMed1989

Plasma desorption mass spectrometry, an analytical tool in protein engineering: characterization of modified insulins.

Californium-252 plasma desorption mass spectrometry (PDMS) has been employed for the characterization of a series of human insulin derivatives in order to evaluate the performance of this technique as an analytical tool in protein engineering. Several of the characterized modifications result in a 1 a.m.u. mass change. The precision in mass determination obtainable by PDMS analysis is not sufficient for unambiguous verification of such modifications based on the molecular weight alone. It is, however, possible to carry out in situ enzymatic digestion of the sample. Subsequent PDMS analysis will in most cases reveal if the modification has been introduced as intended.

Amino Acid Sequence↗
PubMed1985

Crystal and molecular structure of chymotrypsin inhibitor 2 from barley seeds in complex with subtilisin Novo.

The serine proteinase inhibitor from barley seeds, chymotrypsin inhibitor 2(CI-2), has been crystallized in a molecular complex with subtilisin Novo (EC 3.4.21.14). The crystal structure of this complex has been determined at 2.1-A resolution by the molecular replacement method and partially refined by restrained-parameter least-squares methods. The present crystallographic R factor (SigmaFo[unk] - [unk]Fc/Sigma[unk]Fo[unk]) is 0.193. CI-2 is a member of the potato inhibitor 1 family; it is a serine proteinase inhibitor lacking disulfide bonds. Comparison of the subtilisin molecule in this complex with the native subtilisin shows that the two molecules are very similar in structure. The inhibitor binds in a mode presumably resembling that of a true substrate, but it is not cleaved. This is in accord with the reported structures of other serine proteinase-inhibitor complexes. CI-2 consists of a four-stranded mixed parallel and antiparallel beta-sheet against which an alpha-helix packs to form a hydrophobic core. A wide loop crossover connection between parallel strands 2 and 3 of the beta-sheet contains the reactive-site bond. The conformation of the four residues to either side of the reactive-site bond is similar to that of the analogous residues in the third domain of the turkey ovomucoid inhibitor (Kazal family); the overall polypeptide chain fold of these inhibitors and the location of the reactive site in the respective chains are different.

Journal Article↗